On April 30, 2021 Shaperon, a new drug development bio company, reported that it would sign a business agreement (MOU) with Dong-A ST for the joint development of new bio drugs (Press release, Shaperon, APR 30, 2021, View Source;idx=45&pNo=3&code=press_en [SID1234629321]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This joint development agreement was made with the goal of jointly developing treatments for cancer and inflammatory diseases using nanobody-based biopharmaceuticals. Nanobodies are antibodies that are 1/10 the size of existing antibodies, and are attracting attention as a key technology for next-generation immuno-oncology drugs because of their excellent stability and water solubility, high production yield, and high homology with human antibodies, making it easy to develop therapeutics and diagnostic platforms.
The two companies will develop new bio drugs by combining Chaperone’s nanobody technology and Dong-A ST’s new drug development platform. Chaperone builds a nanobody library based on its own technology, develops an antibody suitable for the selected target, verifies the effect at the cellular level, and then proceeds with the effect verification in an animal model in collaboration with Dong-A ST. When efficacy verification is completed in an animal model, Dong-A ST will be in charge of building a cell line for the nanobody antibody. In addition, the two companies plan to jointly discover anti-cancer targets throughout the preclinical process and evaluate the efficacy of candidate antibodies.
Lee Myung-se, CEO of Chaperone, said, "Through this MOU, we expect to see results such as the development of new biologics to treat cancer and chronic inflammation and the creation of corporate value through technology transfer." We will do our best to succeed in commercialization," he said.
Chaperon is the only domestic company that has nanobody development platform technology. In the trend of new drug development, where the structure of protein-based drugs such as bispecific antibodies or antibody drug conjugates is becoming more complex, the side effects and low production efficiency of existing antibodies can be overcome, and various routes of administration such as oral or inhalation are available. It is high tech. Based on the nanobody platform, Chaperon is developing various pipelines such as immune checkpoint inhibitory bispecific antibodies and coronavirus neutralizing antibodies.